Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma

Li, Juan; Li, Ping; Zhao, Wei; Yang, Rui; Chen, Shanshan; Bai, Yong; Dun, Shaozhi; Chen, Xiaonan; Du, Yuwen; Wang, Yuanyuan; Zang, Wenqiao; Zhang, Guojun

doi:10.1186/s12935-015-0201-5

Cited by 72 publications

(61 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most DLX family members play a role in cancer. For example, DLX6 and DLX5 are up‐regulated in metastatic breast cancer cells in lung and bone, and the DLX4 isoform β protein 1 (BP1) is correlated with a poor prognosis in patients with breast cancer . Surprisingly, in the current study, IHC using the polyclonal antibody against DLX6 revealed DLX6 expression in both epithelial cells and myoepithelial cells; thus, we cannot assume that this DLX6 antibody is a specific marker for E‐ACC.…”

Section: Discussioncontrasting

confidence: 68%

In‐depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type

Bell

Bondaruk

et al. 2016

Cancer

View full text Add to dashboard Cite

BACKGROUND: Adenoid cystic carcinoma (ACC), 1 of the most common salivary gland malignancies, arises from the intercalated ducts, which are composed of inner ductal epithelial cells and outer myoepithelial cells. The objective of this study was to determine the genomic subtypes of ACC with emphasis on dominant cell type to identify potential specific biomarkers for each subtype and to improve the understanding of this disease. METHODS: A whole-genome expression study was performed based on 42 primary salivary ACCs and 5 normal salivary glands. RNA from these specimens was subjected to expression profiling with RNA sequencing, and results were analyzed to identify transcripts in epithelial-dominant ACC (E-ACC), myoepithelial-dominant ACC (M-ACC), and all ACC that were expressed differentially compared with the transcripts in normal salivary tissue. RESULTS: In total, the authors identified 430 differentially expressed transcripts that were unique to E-ACC, 392 that were unique to M-ACC, and 424 that were common to both M-ACC and E-ACC. The sets of E-ACC-specific and M-ACC-specific transcripts were sufficiently large to define and differentiate E-ACC from M-ACC. Ingenuity pathway analysis identified known cancer-related genes for 60% of the E-ACC transcripts, 69% of the M-ACC transcripts, and 68% of the transcripts that were common in both E-ACC and M-ACC. Three sets of highly expressed candidate genes-distal-less homeobox 6 (DLX6) for E-ACC; protein keratin 16 (KRT16), SRY box 11 (SOX11), and v-myb avian myeloblastosis viral oncogene homolog (MYB) for M-ACC; and engrailed 1 (EN1) and statherin (STATH), which are common to both E-ACC and M-ACC)-were further validated at the protein level. CONCLUSIONS: The current results enabled the authors to identify novel potential therapeutic targets and biomarkers in E-ACC and M-ACC individually, with the implication that EN1, DLX6, and OTX1 (orthodenticle homeobox 1) are potential drivers of these cancers. Cancer 2016;122:1513-22.

show abstract

Section: Discussioncontrasting

confidence: 68%

In‐depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type

Bell

Bondaruk

et al. 2016

Cancer

View full text Add to dashboard Cite

show abstract

“…Down-regulation of lncRNA DLX6-AS1 expression decreased the DLX6 mRNA and protein levels. 13 However, the role of DLX6-AS1 in renal cell cancer is still unclear.…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA DLX6-AS1 promotes renal cell carcinoma progression via miR-26a/PTEN axis

Zeng

et al. 2017

Cell Cycle

View full text Add to dashboard Cite

Recently, long non-coding RNAs (lncRNAs) have emerged as new gene regulators and prognostic markers in several types of cancer, including renal cell carcinoma (RCC). In this study, we identified an upregulated lncRNA, DLX6-AS1, in RCC tumor tissues compared with normal kidney tissues. Our data suggested that DLX6-AS1 promoted RCC cell growth and tumorigenesis via targeting miR-26a. In addition, we observed that PTEN overexpression restored the renal cancer cell growth and also rescued the RCC tumorigenesis. In summary, we conclude that DLX6-AS1 promotes renal cell carcinoma development via regulation of miR-26a/PTEN axis.

show abstract

“…For example, we predicted that LncRNA DLX6-AS1 could regulate the expressions of FSCN1, SOX11 and PSAT1 through competitive binding to hsa-miR-145. It has been reported that lncRNA DLX6-AS1 was up-regulated in lung adenocarcinoma (LAC) tissues compared to paired adjacent normal lung tissues and high DLX6-AS1 expression levels were significantly associated with both histological differentiation and TNM stage [41]. Recent researches have demonstrated that FSCN1, SOX11 and PSAT1 were associated with poor clinical outcome in breast cancer [42][43][44].…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer

Yang

Liu

Wang

et al. 2018

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

Background/Aims: Triple-negative breast cancer (TNBC) is a subtype of highly malignant breast cancer with poor prognosis. Growing evidence indicates that Long noncoding RNAs (lncRNAs) play important regulatory roles in the development and progression of a variety of cancers including breast cancer. However, the underlying mechanisms remain largely unknown. Methods: Here, we compared the expression profiles of mRNAs, lncRNAs and miRNAs between 111 TNBC tissues and 104 non-cancerous tissues utilizing RNA-Seq Data from The Cancer Genome Atlas (TCGA). Gene Ontology and KEGG pathway enrichment analyses were executed to investigate the principal functions of the significantly dysregulated mRNAs. Moreover, Kaplan-Meier survival analyses were performed to determine the effects of differentially expressed lncRNAs/mRNAs/miRNAs on overall survival. Subsequently, we constructed a competing endogenous RNA (ceRNA) network, which included 66 dysregulated lncRNAs, 24 miRNAs and 55 mRNAs. The four dysregulated lncRNAs, three aberrantly expressed miRNAs and four mRNAs were confirmed in the ceRNA network by qRT-PCR in 30 pairs of samples, respectively. Results: A total of 1441 lncRNAs, 114 miRNA and 2501 mRNAs were found to be differentially expressed in TNBC tissues compared with controls. 109 lncRNAs and 124 mRNAs might serve as prognostic signature for patients with TNBC according to the survival analysis. Functional analysis revealed that 19 mRNAs in the ceRNA network were enriched in 17 cancer-related pathways. Conclusion: Taken together, we identified novel lncRNAs/miRNAs which may serve as potential biomarkers to predict the survival and therapeutic targets for TNBC patients based on a large-scale sample. More importantly, we constructed the ceRNA network of TNBC, which provides valuable information to further explore the molecular mechanism underlying tumorigenesis and development of TNBC.

show abstract

Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma

Cited by 72 publications

References 50 publications

In‐depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type

In‐depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type

Long noncoding RNA DLX6-AS1 promotes renal cell carcinoma progression via miR-26a/PTEN axis

Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer

Contact Info

Product

Resources

About